S

Supernus Pharmaceuticals

D
SUPN
USD
0.27
(0.8477%)
Market Closed
5,706.00
Volume
1.09
EPS
-
Div Yield
356.89
P/E
1,769,985,030.44
Market Cap
Today
0.8477%
1 Week
4.016%
1 Month
-6.054%
6 Months
-8.646%
12 Months
12.900%
Year To Date
11.103%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALKS
0.52
(1.8671%)
USD
A
ACAD
0.11
(0.6736%)
USD
S
SAGE
0.32
(4.2161%)
USD
A
ALNY
3.06
(1.1203%)
USD
E
ESPR
0.01
(0.578%)
USD
E
ESPR
0.01
(0.578%)
USD
I
IONS
0.38
(0.8971%)
USD
A
ARWR
0.35
(1.6851%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD
B
BMRN
0.31
(0.4359%)
USD

Title:
Supernus Pharmaceuticals

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia inPD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Do you need help or have a question?
Contact Us